一品红控股股东承诺：将所持美国Arthrosi公司9.07%的股权无偿给予公司

Core Viewpoint - The company Yipinhong (300723) is set to receive a 9.07% stake in the U.S. company Arthrosi from its controlling shareholder Guangrun Group, supporting the development of its gout innovation drug AR882, amidst a significant acquisition deal involving Arthrosi and Swedish Orphan Biovitrum AB (SOBI) valued at $1.5 billion (approximately 10.6 billion RMB) [1][2][3] Group 1: Acquisition and Stake Transfer - Guangrun Group will transfer its subsidiary Guangrun Health's 9.07% stake in Arthrosi to Yipinhong without any conditions or compensation, reflecting strong confidence in the acquisition and the market potential of AR882 [1][3] - Arthrosi has signed an acquisition agreement with SOBI, which includes an upfront payment of $950 million (approximately 6.713 billion RMB) and potential milestone payments of up to $550 million (approximately 3.887 billion RMB) [1][2] Group 2: Drug Development and Market Position - AR882, a core innovative drug in Arthrosi's pipeline, is currently in critical Phase III clinical trials targeting patients with limited treatment options for gout, particularly those with tophi [2] - The drug has shown effective uric acid reduction and high rates of complete dissolution of tophi in previous Phase II trials, making it a valuable asset for the company [2] Group 3: Strategic Benefits and Financial Impact - The transaction will allow Yipinhong to secure 100% market rights for AR882 in China (including Hong Kong, Macau, and Taiwan) and gain priority in the global supply chain for the drug [3] - The commitment from the controlling shareholder is expected to improve the company's cash flow, enhance asset liquidity, and support the development of more innovative drugs, aligning with the long-term interests of the company and its shareholders [3]